There is nothing exempt from the peril of mutation – The Omicron spike-Reference-Cited by-同舟云学术

There is nothing exempt from the peril of mutation – The Omicron spike

Published:2022-04 Issue: Volume:148 Page:112756
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Behl Tapan,Kaur Ishnoor,Sehgal Aayush,Singh Sukhbir,Sharma Neelam,Anwer Md Khalid,Makeen Hafiz A.,Albratty Mohammed,Alhazmi Hassan A.,Bhatia Saurabh,Bungau Simona

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference85 articles.

1. Crystal structure of CO-bound cytochrome c oxidase determined by serial femtosecond X-ray crystallography at room temperature;Ishigami;Proc. Natl. Acad. Sci. U.S.A.,2017

2. Johns Hopkins Coronavirus Resource Center, (n.d). 〈https://coronavirus.jhu.edu/vaccines/vaccines-faq〉 (accessed December 13, 2021).

3. A global database of COVID-19 vaccinations;Mathieu;Nat. Hum. Behav.,2021

4. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape;Tregoning;Nat. Rev. Immunol.,2021

5. Considerations in boosting COVID-19 vaccine immune responses;Krause;Lancet,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Docking and other computing tools in drug design against SARS-CoV-2;SAR and QSAR in Environmental Research;2024-02

2. Natural Products Based Antibacterial and Antiviral Materials;ACS Symposium Series;2023-12-13

3. The Ways of the Virus: Interactions of Platelets and Red Blood Cells with SARS-CoV-2, and Their Potential Pathophysiological Significance in COVID-19;International Journal of Molecular Sciences;2023-12-09

4. Kinetics of SARS-CoV-2 Spike Antibodies after the Second and Third Dose of the BNT162b2 COVID-19 Vaccine and Association with Epidemiological Characteristics and Breakthrough Infection in a Cohort Study of Healthcare Workers;Microorganisms;2023-08-04

5. C-reactive protein to lymphocyte ratio is a significant predictive factor for poor short-term clinical outcomes of SARS-CoV-2 BA.2.2 patients;Frontiers in Public Health;2023-04-06